Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.23.3
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Condensed Consolidated Statements of Operations and Comprehensive Loss    
Revenues $ 50  
Operating expenses:    
Research and development 1,606 $ 2,548
General and administrative 3,547 5,088
Total operating expenses 5,153 7,636
Operating loss (5,103) (7,636)
Other income (expense):    
Interest expense (26)  
Interest income 55 99
Total other income 29 99
Net loss available to iBio, Inc. stockholders from continuing operations (5,074) (7,537)
Loss from discontinued operations (672) (10,593)
Net loss available to iBio, Inc. stockholders (5,746) (18,130)
Comprehensive loss:    
Consolidated net loss (5,746) (18,130)
Other comprehensive loss - unrealized loss on debt securities   (10)
Comprehensive loss $ (5,746) $ (18,140)
Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations $ (0.21) $ (0.85)
Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations (0.21) (0.85)
Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations (0.03) (1.20)
Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations (0.03) (1.20)
Loss per common share attributable to iBio, Inc. stockholders - basic - total (0.24) (2.05)
Loss per common share attributable to iBio, Inc. stockholders - diluted - total $ (0.24) $ (2.05)
Weighted-average common shares outstanding - basic 23,969 8,842
Weighted-average common shares outstanding - diluted 23,969 8,842